Sergio Facchini

🩺MD, GI Oncologist - 🎓Università degli Studi della Campania “Luigi Vanvitelli”- 🏥 INT IRCCS Fondazione “G. Pascale”

[Daisuke Kotani, MD, Ph.D 小谷 大輔 @DaisukeKotani]

Letter to the Editor (TRIPLETE study)
1⃣Non-proportional hazards
OS diverge late (~22 mo). 5y RMST shows a more modest OS benefit (+2.9 mo, p=0.14) compared to the median.
🔗https://t.co/WLebwh6eg1

2⃣Post-progression therapy bias
Higher anti-EGFR reinduction rates in the triplet arm (31% vs 20%) might have artificially inflated OS.
🔗https://t.co/L8iJq217i7
@JCO_ASCO @OncoAlert

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 TRIPLETE OS debate

📩 Comment: OS advantage be driven by more frequent anti-EGFR reinduction after PD?

📩 Reply: Reinduction may play a role, but OS differences persisted even after excluding these pts.

🎯 The true reason for the late OS benefit remains unresolved.

🔗 https://t.co/axNTCVC2ch
🔗 https://t.co/hxIAZo1Ih2

@OncoAlert

[Sergio Facchini @DrSFacchini]

🚨 Proud to share our latest publication in Cancer Treatment Reviews!

Our meta-analysis explores the role of postoperative ctDNA in mCRC pts treated with curative intent 🧬

Great teamwork with @clacardone and @AscefBruna 🙌

https://t.co/eUsVTsvow3

#mCRC #ctDNA #Oncology

[Erman Akkus @Erman_Akkus]

Prognostic role of postoperative circulating tumor DNA in metastatic colorectal cancer treated with curative intent: A systematic review and meta-analysis - Cancer Treatment Reviews https://t.co/byFvape4tm

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧪 STRIDE (Durva + treme) in resectable MSI-H GC /GEJ (#AACR2026, CT230)
📊 Phase II INFINITY – Cohort 2 (n=18)
🔹 cCR 76% → NOM strategy
🔹 2y cCR rate 67%
🔹 24-mo PFS 94% | OS 100% | GFS 70.6%
🔹 G≥3 irAEs: 3 pts
💥 1st long-term data supporting NOM

🔗 https://t.co/tWbnUSSAPZ
@OncoAlert @AACR @GrupoTTD

[Arndt Vogel @ArndtVogel]

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
@Annals_Oncology
https://t.co/HvqcPy5bdq
👉get the latest updates in CRC
@myESMO @ASCO

[Josh Farkas MD 💊 @PulmCrit]

modern IV contrast dye for CT scans isn’t neprotoxic.

definitive imaging saves lives.

this is so simple but people & journals & textbooks keep on messing it up.

[ESMO Open @ESMO_Open]

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study in @ESMO_Open.Improved PFS & DCR with FTD-TPI Bev, including KRAS p.G12C mCRC. https://t.co/HDrVKI40R1

[Sergio Facchini @DrSFacchini]

Such an incredible experience in the eternal city.
Wonderful lectures, mind-opening discussions.
Thank you @AIOMtweet and @ASCO for this great opportunity.
#Oncology #ClinicalResearchCourse

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🚀 ABACO: Phase II CABO in mCRC (≥2 L)
• Primary endpoint met: PFS 16w 33%
• mPFS 2.27 mo | mOS 6.25 mo | DCR 45.5%
• Manageable safety
• better outcomes TP53 WT + TMB ≥4 muts/Mb and EMT/angiogenesis (CMS4)

➡️ Modest activity; molecular selection may optimize benefit.
@OncoAlert
https://t.co/iFJukYDXpk

[Dr. Nina Niu Sanford @NiuSanford]

SOFT study: 141 elderly (70+), chemo-ineligible pts w locally advanced rectal cancer.

Short-course RT → delayed surgery achieved 94% R0 resection & 5% local recurrence.

A v reasonable, low-burden strategy for older pts w competing risks. @OncoAlert

https://t.co/ZD1MYC6j5E

[Arndt Vogel @ArndtVogel]

Survival impact of hepatitis C virus eradication in patients with or without active HCC: A nationwide cohort study
https://t.co/nW7Y1yKaGH
❓Who should be treated
🧐Interesting:
👉 BCLC stage 0/A, early DAA is recommended, even with active HCC
👉 BCLC stage B/C, DAA therapy appears most beneficial after tumor control
@myESMO @EASLedu @ILCAnews

[Arndt Vogel @ArndtVogel]

Zanidatamab in HER2-PositiveMetastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01
@JAMAOnc
https://t.co/HPc934ZhB9
👉IHC 3+: cORR 51.6% & mOS 18.1 mo
👉IHC 2+: cORR, 5.6% & mOS 5.2 mo
🧐Stong signal of efficacy in IHC3+, IHC is key for pts selection

[Arndt Vogel @ArndtVogel]

MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma
#ESMO25 #ESMOAmbassadors
👉 pCR: 16%, MPR: 26%, any: 87%
👉 OS: HR: 0.78; 36-mo OS: 68 vs 61%
🧐OS improved independent of TAP, better in responders > new SOC
@myesmo

[Timothée Olivier, MD @Timothee_MD]

https://t.co/immidRjQVs

[Erman Akkus @Erman_Akkus]

📢🟠ATOMIC
#ASCO25

➡️Adj atezolizumab + FOLFOX vs FOLFOX in stage III dMMR colon ca

✅3-y DFS: 86.4% vs 76.6%
HR: 0.50, P<0.0001

@OncoAlert @ASCO #cancer #oncology #MedX #colon

[Arndt Vogel @ArndtVogel]

Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP) #ASCO25
👉Enhanced prognostic prediction
👉Robust validation
@myESMO

[NEJM @NEJM]

Presented at #ASCO25:

A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: https://t.co/j3kWJDjuVz

@ASCO

[Arndt Vogel @ArndtVogel]

🔥Plenary Discussion of LBA5🔥
📷 #ASCO2025
👏Great discussion by @KlempnerSam
👉D-FLOT reached it's primary endpoint and will change clinical practice
👉More to come: from MATTERHORN to EVEREST
@myESMO

[Yakup Ergün @dr_yakupergun]

#ASCO25 @NEJM
BREAKWATER: Encorafenib + cetuximab + mFOLFOX6 vs standard care in 1L BRAF V600E mCRC

PFS➡️12.8 vs 7.1 mo✅️
OS➡️ 30.3 vs 15.1 mo✅️👏

💥For one of the hardest-to-treat mCRC subtypes, this triplet shows substantial survival benefit.

https://t.co/dzjsTD9wiF